Explore licensed vaccines, adverse event reporting data, and history for this disease.
- Phase 1
- Phase 2
- Phase 3
- Filed
- Approved
Multi-Jurisdiction Regulatory Status
Official licensing, rolling submissions, or authorization status tracked across major health authorities.
| Regulatory Authority | Status & Details |
|---|---|
| US FDA | Approved / Authorized mRESVIA approved for indicated adult groups; pipeline may include expanded indications — check current label; Date as recorded by the curator: "2024+" |
| EMA (Europe) | Not Filed / Pre-submission |
| Health Canada | Not Filed / Pre-submission |
| TGA (Australia) | Not Filed / Pre-submission |
Progress and adoption outlook
Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Stage known from the trial registry only; no jurisdiction-specific filing date.
- Preclinical
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Submitted to a regulator
- Under regulatory review
- Approved / authorised
- Recommended for routine use
Current position: Approved / authorised
| Jurisdiction | Status in the record | Submission | Regulator decision | Earliest routine use |
|---|---|---|---|---|
| United StatesFDA (CBER) · ACIP (CDC) | approved | — | 2026-102026-10 to 2026-10 | 2027-012026-10 to 2027-06 |
| European UnionEMA (CHMP) and European Commission · national bodies (STIKO, HAS, Folkhälsomyndigheten and others) | no jurisdiction-specific filing known | 2026-102026-10 to 2026-10 | 2027-122027-07 to 2028-06 | 2028-062027-08 to 2029-12 |
| CanadaHealth Canada · NACI | no jurisdiction-specific filing known | 2026-102026-10 to 2026-10 | 2027-082027-04 to 2028-01 | 2027-122027-05 to 2029-01 |
| United KingdomMHRA · JCVI | no jurisdiction-specific filing known | The MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used. | ||
| AustraliaTGA · ATAGI | no jurisdiction-specific filing known | TGA registration-timeframe pages timed out on 2026-10-24; no target is used. | ||
| JapanPMDA / MHLW · MHLW immunisation subcommittee | no jurisdiction-specific filing known | PMDA English pages reached on 2026-10-24 state that target review times exist but give no figure. | ||
| WHO prequalificationWHO Prequalification · SAGE | no jurisdiction-specific filing known | WHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used. | ||
Each window shows the typical scenario with the fast-to-slow band beneath it (year-month). Bands come from the parameters on the outlook model page; they are not forecasts.
Scientific Profile & Documentation
- Platform Architecture
- mRNA
- Lead Developer
- Moderna
- Next Expected Milestone
- Label expansions / seasonal updates as disclosed; see licensed RSV page for post-licensure safety
- Analyst & Development Notes
- When a candidate is approved, the site loop closes to the licensed vaccine evidence page (rsv-vaccine.html).
- Primary Source Documentation
- FDA vaccines licensed for use in the United States →
Registered Clinical Trials & Studies
Direct registry links to active, completed, or pivotal registration studies across phases.
No primary ClinicalTrials.gov record linked directly. Study data tracked via regulatory submission filings and peer-reviewed releases.
Milestone Overview
-
Stage VerificationApproved / Licensed confirmed as of 2026-07-10.
-
Target MilestoneLabel expansions / seasonal updates as disclosed; see licensed RSV page for post-licensure safety
Vaccine Data Navigator Candidate Profile Registry:
This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.